Benefit-risk assessment of sirolimus in renal transplantation

Drug Safety

Volumn 28, Issue 2, 2005, Pages 153-181

  Kuypers, Dirk R J ^a,b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b Dept of Nephrol/Ren Transplant ^*  (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ANIMAL MODEL; BONE MARROW SUPPRESSION; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ENDOCRINE DISEASE; FERTILITY; FETOTOXICITY; GASTROINTESTINAL TOXICITY; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTIOUS COMPLICATION; KIDNEY ALLOGRAFT REJECTION; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LIVER TOXICITY; LUNG TOXICITY; LYMPHOCELE; MAJOR CLINICAL STUDY; METABOLIC DISORDER; MUSCULOSKELETAL DISEASE; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; ORGAN TRANSPLANTATION; OSTEOPOROSIS; PREGNANCY; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SKIN TOXICITY; THROMBOCYTOPENIA; WOUND HEALING;

ANIMALS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; SIROLIMUS;

EID: 14644403072     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200528020-00006     Document Type: Review

References (231)

1. Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc 2003; 35 Suppl. 3 A: 7S-14S
2. Kirken RA, Wang YL. Molecular actions of sirolimus: sirolimus and mTOR. Transplant Proc 2003; 35 Suppl. 3A: 227S-30S
3. Dumont FJ, Qingxiang S. Mechanism of action of the immunosuppressant rapamycin. Life Sci 1996; 58 (5): 373-95
4. Stepkowski SM. Preclinical results of sirolimus treatment in transplant models. Transplant Proc 2003; 35 Suppl. 3A: 219S-26S
5. Moon JI, Kim YS, Kim EH. Effect of cyclosporine, mycophenolic acid, and rapamycin on the proliferation of rat aortic vascular smooth muscle cells: in vitro study. Transplant Proc 2000; 32: 2026-7
6. Marks AR. Rapamycin: signaling in vascular smooth muscle. Transplant Proc 2003; 35 Suppl. 3A: 231S-3S
7. Gregory C, Huie P, Billingham ME, et al. Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury. Transplantation 1993; 55 (6): 1409-18
8. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349 (14): 1315-25
9. Lemos PA, Saia F, Hofma SH, et al. Short- and long-term clinical benefit of sirolimus-eluting stents compared to conventional bare stents for patients with acute myocardial infarction. J Am Coll Cardiol 2004; 43 (4): 704-8
10. Luan FL, Ding R, Sharma VK, et al. Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int 2003; 63: 917-26
11. Majewski M, Korecka M, Joergensen J, et al. Immunosuppressive TOR kinase inhibitor everolimus (RAD) supresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses. Transplantation 2003; 75 (10): 1710-7
12. MacDonald A, Scarola J, Burke JT, et al. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. Clin Ther 2000; 22 Suppl. B: B101-20
13. Mahalati K, Kahan BD. Clinical pharmacokinetics of sirolimus. Clin Pharmacokinet 2001; 40 (8): 573-85
14. Holt DW, Denny K, Lee D, et al. Therapeutic monitoring of sirolimus: its contribution to optimal prescription. Transplant Proc 2003; 35 Suppl. 3A: 157S-61S
15. Aspeslet LJ, Yatscoff RW. Requirements for therapeutic drug monitoring of sirolimus, an immunosuppressive agent used in renal transplantation. Clin Ther 2000; 22 Suppl. B: B86-92
16. Podder H, Stepkowski SM, Napoli KL, et al. Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. J Am Soc Nephrol 2001; 12: 1059-71
17. Kreis H, Cisterne JM, Land W, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69: 1252-60
18. Kuypers DRJ, Claes K, Evenepoel P, et al. Long-term pharmacokinetic study of the novel combination of tacrolimus and sirolimus in de novo renal allograft recipients. Ther Drug Monit 2003; 25 (4): 447-51
19. Meier-Kriesche HU, Kaplan B. Toxicity and efficacy of sirolimus: relationship to whole-blood concentrations. Clin Ther 2000; 22 Suppl. B: B93-B100
20. Kahan BD, Napoli KL, Kelly PA, et al. Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity. Clin Transplant 2000; 14: 97-109
21. Groth CG, Bäckman L, Morales JM, et al. Sirolimus (rapamycin): based therapy in human renal transplantation. Transplantation 1999; 67: 1036-42
22. Flechner SM, Goldfarb D, Modlin C, et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomised trial of sirolimus versus cyclosporine. Transplantation 2002; 74 (8): 1070-6
23. Oberbauer R, Kreis H, Johnson R, et al. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the rapamune maintenance regimen study. Transplantation 2003; 76 (2): 364-70
24. McAlister VC, Mahalati K, Peltekian KM, et al. A clinical pharmacokinetic study of tacrolimus and sirolimus combination immunosuppression comparing simultaneous to separated administration. Ther Drug Monit 2002; 24: 346-50
25. Kahan BD. Efficacy of sirolimus compare with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet 2000; 356: 194-202
26. Solez K, Axelsen RA, Benediktsson H, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplantation. Kidney Int 1993; 44 (2): 411-22
27. MacDonald AS, RAPAMUNE Global Study Group. A worldwide, phase III, randomised, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 71 (2): 271-80
28. Kahan BD, Julian BA, Pescovitz MD, et al. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in Caucasian recipients of mismatched primary renal allografts: a phase II trial. Transplantation 1999; 68 (10): 1526-32
29. Podder H, Podbielski J, Hussein I, et al. Sirolimus improves the two-year outcome of renal allografts in African-American patients. Transpl Int 2001; 14: 135-42
30. Zimmerman JJ, Kahan BD. Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. J Clin Pharmacol 1997; 37: 405-15
31. Kovarik JM, Hsu CH, McMahon L, et al. Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications. Clin Pharmacol Ther 2001; 70: 247-54
32. Stepkowski SM, Napoli KL, Wang ME, et al. Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats. Transplantation 1996; 62 (7): 986-94
33. Shihab FS, Bennett WM, Yi H, et al. Sirolimus increases transforming growth factor-β1 expression and potentiates chronic cyclosporine nephrotoxicity. Kidney Int 2004; 65: 1262-71
34. Andoh TF, Lindsley J, Franceschini N, et al. Synergistic effects of cyclosporine and rapamycin in a chronic nephrotoxicity model. Transplantation 1996; 62 (3): 311-6
35. Formica Jr RN, Lorber KM, Friedman AL, et al. Sirolimus-based immunosuppression with reduce dose cyclosporine or tacrolimus after renal transplantation. Transplant Proc 2003; 35 Suppl. 3A: 95S-8S
36. Wiseman AC, Kam I, Christians U, et al. Fixed-dose sirolimus with reduced dose calcineurin inhibitor: the University of Colorado experience. Transplant Proc 2003; 35 Suppl. 3A: 122S-4S
37. Hong JC, Kahan BD. Use of anti-CD25 monoclonal antibody in combination with rapamycin to eliminate cyclosporine treatment during the induction phase of immunosuppression. Transplantation 1999; 68 (5): 701-4
38. Langer RM, Hong DM, Katz SM, et al. Basiliximab-sirolimus-prednisone induction regimen followed by delayed low-dose cyclosporine in renal transplant recipients of living donors. Transplant Proc 2002; 34: 3162-4
39. Kuypers DR, Chapman JR, O'Connell PJ, et al. Predictors of renal transplant histology at three months. Transplantation 1999; 67 (9): 1222-30
40. Kreis H, Oberbauer R, Campistol JM, et al. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 2004; 15: 809-17
41. Gonwa TA, Hricik DE, Brinker K, et al. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Transplantation 2002; 74 (11): 1560-7
42. Baboolal K. A phase III prospective, randomised study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients. Transplantation 2003; 75 (8): 1404-8
43. Johnson RW, Kreis H, Oberbauer R, et al. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001; 72 (5): 777-86
44. Mota A, Arias M, Taskinen E, et al. Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant 2004; 4 (6): 953-61
45. Yilmaz S, Tomlanovich S, Mathew T, et al. Protocol core needle biopsy and histologic chronic allograft damage index (CADI) as surrogate end point for long-term graft survival in multicenter studies. J Am Soc Nephrol 2003; 14: 773-9
46. Nankivell BJ, Fenton-Lee CA, Kuypers DR, et al. Effect of histological damage on long-term kidney transplant outcome. Transplantation 2001; 71 (4): 515-23
47. Morales JM, Wramner L, Kreis H, et al. Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant 2002; 2: 436-42
48. Stegall MD, Larson TS, Prieto M, et al. Kidney transplantation without calcineurin inhibitors using sirolimus. Transplant Proc 2003; 35 Suppl. 3A: 125S-7S
49. Shaffer D, Langone A, Nylander WA, et al. A pilot protocol of a calcineurin inhibitor free regimen for kidney transplant recipients of marginal donor kidneys or with delayed graft function. Clin Transplant 2003; 17 Suppl. 9: 31-4
50. Chang GJ, Mahanty HD, Vincenti F, et al. A calcineurin inhibitor-sparing regimen with sirolimus, mycophenolate mofetil, and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function. Clin Transplant 2000; 14: 550-4
51. Flechner S, Kurian SM, Solez K, et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 2004; 4: 1776-85
52. Kahan BD, Knight R, Schoenberg L, et al. Ten years of sirolimus therapy for human renal transplantation: the University of Texas at Houston experience. Transplant Proc 2003; 35 Suppl. 3A: 25S-34S
53. Vincenti F, Stock P. De novo use of sirolimus in immunosuppression regimens in kidney and kidney-pancreas transplantation at the University of California, San Francisco. Transplant Proc 2003; 35 Suppl. 3A: 183S-6S
54. Stegall MD, Larson TS, Prieto M, et al. Living-donor kidney transplantation at Mayo Clinic - Rochester. Clin Transpl 2002; 155-61
55. Grimbert P, Baron C, Fruchaud G, et al. Long-term results of a prospective randomised study comparing two immunosuppressive regimens, one with and one without CsA, in low-risk transplant recipients. Transpl Int 2002; 15 (11): 550-5
56. Vincenti F, Ramos E, Brattstrom C, et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2001; 71: 1282-7
57. Shihab FS, Bennett WM, Yi H, et al. Combination therapy with sirolimus and mycophenolate mofetil: effects on the kidney and on transforming growth factor-[beta]1. Transplantation 2004; 77 (5): 683-6
58. Undre NA. Pharmacokinetics of tacrolimus-based combination therapies. Nephrol Dial Transplant 2003; 18 Suppl. 1: 12-5
59. van Hooff JP, Squifflet JP, Wlodarczyk Z, et al. A prospective randomized multicenter study of tacrolimus in combination with sirolimus in renal-transplant recipients. Transplantation 2003; 75 (12): 1934-9
60. Gonwa T, Johnson C, Ahsan N, et al. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years. Transplantation 2003; 75 (12): 2048-53
61. Squifflet JP, Backman L, Claesson K, et al. Dose optimisation of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients. Transplantation 2001; 72 (1): 63-9
62. Balupuri S, Buckley P, Snowden C, et al. The trouble with kidneys derived from the non heart-beating donor: a single center 10-year experience. Transplantation 2000; 69 (5): 842-6
63. Paczek L, Bechstein WO, Wramner L, et al. An open-label, concentration-controlled, randomised 6-month study of standard-dose tacrolimus + sirolimus + steroids compared to reduced-dose tacrolimus + sirolimus + steroids in renal allograft recipients [abstract]. Am J Transplant 2003; 3 Suppl. 5: 464
64. Russ GR, Campbell S, Chadban S, et al. Reduced and standard target concentration tacrolimus with sirolimus in renal allograft recipients. Transplant Proc 2003; 35 Suppl. 3: 115S-7S
65. Lo A, Egidi MF, Gaber LW, et al. Observations regarding the use of sirolimus and tacrolimus in high-risk cadaveric renal transplantation. Clin Transplant 2004; 18: 53-61
66. Ciancio G, Burke GW, Gaynor JJ, et al. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (neoral) and sirolimus in renal transplantation: I. drug interactions and rejection at one year. Transplantation 2004; 77 (2): 244-51
67. Ciancio G, Burke GW, Gaynor JJ, et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (neoral)/sirolimus in renal transplantation: II. Survival, function, and protocol compliance at 1 year. Transplantation 2004; 77 (2): 252-8
68. Grinyo JM, Campistol JM, Paul J, et al. Pilot randomized study of early tacrolimus withdrawal from a regimen with sirolimus plus tacrolimus in kidney transplantation. Am J Transplant 2004; 4: 1308-14
69. Shapiro R, Scantlebury VP, Jordan ML, et al. A pilot trial of tacrolimus, sirolimus, and steroids in renal transplant recipients. Transplant Proc 2002; 34: 1651-2
70. El-Sabrout R, Delaney V, Qadir M, et al. Sirolimus in combination with tacrolimus or mycophenolate mofetil for minimizing acute rejection risk in renal transplant recipients: a single center experience. Transplant Proc 2003; 35 Suppl. 3A: 89S-94S
71. Hricik DE, Knauss TC, Bodziak KA, et al. Withdrawal of steroid therapy in African American kidney transplant recipients receiving sirolimus and tacrolimus. Transplantation 2003; 76 (6): 938-42
72. Lo A, Egidi MF, Gaber LW, et al. Comparison of sirolimus-based calcineurin inhibitor-sparing and calcineurin inhibitor-free regimens in cadaveric renal transplantation. Transplantation 2004; 77 (8): 1228-35
73. Chen H, Wu J, Xu D, et al. Reversal of ongoing heart, kidney, and pancreas allograft rejection and suppression of accelerated heart allograft rejection in the rat by rapamycin. Transplantation 1993; 56: 661-6
74. Hong JC, Kahan BD. Sirolimus rescue therapy for refractory rejection in renal transplantation. Transplantation 2001; 7(11): 1579-84
75. Slaton JW, Kahan BD. Case report: sirolimus rescue therapy for refractory renal allograft rejection. Transplantation 1996; 61 (6): 977-9
76. Straatman LP, Coles JG. Pediatric utilization of rapamycin for severe cardiac allograft rejection. Transplantation 2000; 70 (3): 541-3
77. Sindhi R, Webber S, Venkataramanan R, et al. Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus. Transplantation 2001; 72 (5): 851-5
78. Ikonen TS, Gummert JF, Hayase M, et al. Sirolimus (rapamycin) halts and reverses progression of allograft vascular disease in non-human primates. Transplantation 2000; 70 (6): 969-75
79. Poston RS, Billingham M, Grant Hoyt E, et al. Rapamycin reverses chronic graft vascular disease in a novel cardiac allograft model. Circulation 1999; 100 (1): 67-74
80. Nair S, Eason J, Loss G. Sirolimus monotherapy in nephrotoxicity due to calcineurin inhibitors in liver transplant recipients. Liver Transpl 2003; 9 (2): 126-9
81. Chang GJ, Mahanty HD, Quan D, et al. Experience with the use of sirolimus in liver transplantation-use in patients for whom calcineurin inhibitors are contraindicated. Liver Transpl 2000; 6 (6): 734-40
82. Groetzner J, Meiser B, Landwehr P, et al. Mycophenolate mofetil and sirolimus as calcienurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure. Transplantation 2004; 77 (4): 568-74
83. Ussetti P, Laporta R, de Pablo A, et al. Rapamycin in lung transplantation: preliminary results. Transplant Proc 2003; 35: 1974-7
84. Dominguez J, Mahalati K, Kiberd B, et al. Conversion to rapamycin immunosuppression in renal transplant recipients: report of an initial experience. Transplantation 2000; 70 (8): 1244-7
85. Diekmann F, Waiser J, Fritsche L, et al. Conversion to rapamycin in renal allograft recipients with biopsy-proven calcineurin inhibitor-induced nephrotoxicity. Transplant Proc 2001; 33: 3234-5
86. Citterlo F, Scatà MC, Violi P, et al. Rapid conversion to sirolimus for chronic progressive deterioration of the renal function in kidney allograft recipients. Transplant Proc 2003; 35: 1292-4
87. Morelon E, Kreis H. Sirolimus therapy without calcineurin inhibitors: necker hospital 8-year experience. Transplant Proc 2003; 35 Suppl. 3A: 52S-7S
88. Sundberg AK, Rohr MS, Hartmann EL, et al. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients. Clin Transplant 2004; 18 Suppl. 12: 61-6
89. Saunders RN, Bicknell GR, Nicholson ML. The impact of cyclosporine dose reduction with or without the addition of rapamycin on functional, molecular, and histological markers of chronic allograft nephropathy. Transplantation 2003; 75 (6): 772-80
90. Napoli KL, Wang ME, Stepkowski SM, et al. Relative tissue distributions of cyclosporin and sirolimus after concomitant peroral administration in the rat: evidence for pharmacokinetic interactions. Ther Drug Monit 1998; 20 (2): 123-33
91. Stallone G, Di Paolo S, Schena A, et al. Early withdrawal of cyclosporine A improves 1-year kidney graft structure and function in sirolimus-treated patients. Transplantation 2003; 75 (7): 998-1003
92. Diekmann F, Budde K, Oppenheimer F, et al. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 2004; 4: 1869-75
93. Li Y, Zheng XX, Li XC, et al. Combined costimulation blockade plus rapamycin but not cyclosporine produces permanent engraftment. Transplantation 1998; 66 (10): 1387-8
94. Sho M, Sandner SE, Najafian N, et al. New insights into the interactions between T-cell costimulatory blockade and conventional immunosuppressive drugs. Ann Surg 2002; 236 (5): 667-75
95. Knechtle SJ, Pirsch JD, Fechner Jr H, et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant 2003; 3: 722-30
96. Kirk AD, Hale DA, Mannon RB, et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (campath-1H). Transplantation 2003; 76 (1): 120-9
97. Swanson SJ, Hale DA, Mannon RB, et al. Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy. Lancet 2002; 360: 1662-4
98. Andoh TF, Burdmann EA, Eransechini N, et al. Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK-506. Kidney Int 1996; 50: 1110-7
99. Thliveris JA, Yatscoff RW. Effect of rapamycin on morphological and functional parameters in the kidney of the rabbit. Transplantation 1995; 59 (3): 427-9
100. Goldbaekdal K, Nielsen CB, Djurhuus JC, et al. Effects of rapamycin on renal hemodynamics, water and sodium excretion, and plasma levels of angiotensin II, aldosterone, atrial natriuretic peptiden and vasopressin in pigs. Transplantation 1994; 58(11): 1153-7
101. DiJoseph JF, Sharma RN, Chang JY. The effect of rapamycin on kidney function in the Sprague-Dawley rat. Transplantation 1992; 53 (3): 507-13
102. DiJoseph JF, Mihatsch MJ, Sehgal SN. Renal effects of rapamycin in the spontaneously hypertenive rat. Transpl Int 1994; 7: 83-8
103. Sabbatini M, Sansone G, Ucello F, et al. Acute effects of rapamycin on glomerular dynamics: a micropuncture study in the rat. Transplantation 2000; 69 (9): 1946-9
104. DiJoseph JF, Sehgal SN. Functional and histopathologic effects of rapamycin on mouse kidney. Immunopharmacol Immunotoxicol 1993; 15 (1): 45-56
105. Lieberthal W, Fuhro R, Andry CC, et al. Rapamycine impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cells. Am J Renal Physiol 2001; 281: F693-706
106. Fuller TF, Freise CE, Serkova N, et al. Sirolimus delays recovery of rat kidney transplants after ischemia-reperfusion injury. Transplantation 2003; 76 (11): 1594-9
107. Niemann CU, Saeed M, Akbari H, et al. Close association between the reduction in myocardial energy metabolism and infarct size: dose-response assessment of cyclosporine. J Pharmacol Exp Ther 2002; 302 (3): 1123-8
108. Edinger AL, Linardic CM, Chiang GG, et al. Differential effects of rapamycin on mammalian target of rapamycin signalling functions in mammalian cells. Cancer Res 2003; 63: 8451-60
109. Simon N, Morin C, Urien S, et al. Tacrolimusrolimus and sirolimus decrease oxidative phosphorylation of isolated rat kidney mitochondria. Br J Pharmacol 2003; 138 (2): 369-76
110. Nielsen FT, Ottosen P, Starklint H, et al. Kidney function and morphology after short-term combination therapy with cyclosporine A. tacrolimus and sirolimus in rat. Nephrol Dial Transplant 2003; 18: 491-6
111. Lawsin L, Light JA. Severe acute renal failure after exposure to sirolimus-tacrolimus in two living donor kidney recipients. Transplantation 2003; 75 (1): 157-60
112. Smith KD, Wrenshall LE, Nicosia RF, et al. Delayed graft function and cast nephropathy associated with tacrolimus plus rapamycin use. J Am Soc Nephrol 2003; 14: 1037-45
113. McTaggart RA, Gottlieb D, Brooks J, et al. Sirolimus prolongs recovery from delayed graft function after cadaveric renal transplantation. Am J Transplant 2003; 3: 416-23
114. Stallone G, Di Paolo S, Schena A, et al. Addition of sirolimus to cyclosporine delays the recovery from delayed graft function but does not affect 1-year graft function. J Am Soc Nephrol 2004; 15: 228-33
115. Morales JM, Andrés A, Dominguez-Gil B, et al. Tubular function in patients with hypokalemia induced by sirolimus after renal transplantation. Transplant Proc 2003; 35 Suppl. 3A: 154S-6S
116. Charpentier B. Bicêtre Hospital experience with sirolimus-based therapy in human renal transplantation: the Sirolimus European Renal Transplant Study. Transplant Proc 2003; 35 Suppl. 3A: 58S-61S
117. Schwarz C, Böhmig GA, Steininger R, et al. Impaired phosphate handling of renal allografts is aggravated under rapamycin-based immunosuppression. Nephrol Dial Transplant 2001; 16: 378-82
118. Caravaca F, Fernandez MA, Ruiz-Calero R, et al. Effects of oral phosphorus supplementation on mineral metabolism of renal transplant recipients. Nephrol Dial Transplant 1998; 13: 2605-11
119. Wyzgal J, Paczek L, Senatorski G, et al. Sirolimus rescue treatment in calcineurin inhibitor nephrotoxicity after kidney transplantation. Transplant Proc 2002; 34: 3185-7
120. Radermacher J, Meiners M, Bramlage C, et al. Pronounced renal vasoconstriction and systemic hypertension in renal transplant patients treated with cyclosporin A versus KF506. Transpl Int 1998; 11 (1): 3-10
121. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326-33
122. Daniel C, Ziswiler R, Frey B, et al. Proinflammatory effects in experimental mesangial proliferative glomerulonephritis of the immunosuppressive agent SDZ RAD, a rapamycin derivative. Exp Nephrol 2000; 8: 52-62
123. Wang W, Chan YH, Lee W, et al. Effects of rapamycin and FK506 on mesangial cell proliferation. Transplant Proc 2001; 33: 1036-7
124. Fervenza FC, Fitzpatrick PM, Mertz J, et al. Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies. Mayo Nephrology Collaborative Committee. Nephrol Dial Transplant 2004; 19: 1288-92
125. Dittrich E, Schmaldienst S, Soleimn A, et al. Rapamycin-associated posttransplant glomerulonephritis and its complete remission after reintroduction of calcineurin inhibitor therapy. Transplant Int 2004; 17 (4): 215-20
126. Chueh SJ, Kahan BD. Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen: incidence, risk factors, progression, and prognosis. Transplantation 2003; 76 (2): 375-82
127. Hoogeveen RC, Ballantyne CM, Pownall HJ, et al. Effect of sirolimus on the metabolism of ApoB100-containing lipoproteins in renal transplant patients. Transplantation 2001; 72 (7): 1244-50
128. Tur MD, Carrigue V, Vela C, et al. Apolipoprotein CIII is upregulated by anticalcineurins and rapamycin: implications in transplantation-induced dyslipidemia. Transplant Proc 2000; 32: 2783-4
129. Morrisett JD, Abdel-Fattah G, Hoogeveen R, et al. Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res 2002; 43: 1170-80
130. Brattström C, Wilczek HE, Tydén G, et al. Hypertriglyceridemia in renal transplant recipients treated with sirolimus. Transplant Proc 1998; 30: 3950-1
131. Blum CB. Effects of sirolimus on lipids in renal allograft recipients: an analysis using the Framingham risk model. Am J Transplant 2002; 2: 551-9
132. Rigatto C. Clinical epidemiology of cardiac disease in renal transplant recipients. Semin Dial 2003; 16 (2): 106-10
133. Langer RM, Kahan BD. Sirolimus does not increase the risk for postoperative thromboembolic events among renal transplant recipients. Transplantation 2003; 76 (2): 318-23
134. Trotter JF, Wachs ME, Trouillot TE, et al. Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not tacrolimus. Liver Transpl 2001; 7 (5): 401-8
135. McAlister VC, Gao Z, Peltekian K, et al. Sirolimus-tacrolimus combination immunosuppression. Lancet 2000; 355: 376-7
136. Fabian MC, Lakey JR, Rajotte RV, et al. The efficacy and toxicity of rapamycin in murine islet transplantation: in vitro and in vivo studies. Transplantation 1993; 56 (5): 1137-42
137. Fuhrer DK, Kobayashi M, Jiang H. Insulin release and suppression by tacrolimus, rapamycin and cyclosporin A are through regulation of the ATP-sensitive potassium channel. Diabetes Obes Metab 2001; 3: 393-402
138. Shapiro AM, Suarez-Pinzon WL, Power R, et al. Combination therapy with low dose sirolimus and tacrolimus is synergistic in preventing spontaneous and recurrent autoimmune diabetes in non-obese diabetic mice. Diabetologia 2002; 45 (2): 224-30
139. Kasiske BL, Snyder JJ, Gilbertson D, et al. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3 (2): 178-85
140. Bererhi L, Flamant M, Martinez F, et al. Rapamycin-induced oligospermia. Transplantation 2003; 76 (5): 885-6
141. Morris RE. Rapamycins: antifungal, antitumor, antiproliferative and immunosuppressive macrolides. Transplant Rev 1992; 6: 39-87
142. Fritsche L, Budde K, Dragun D, et al. Testosterone concentrations and sirolimus in male renal transplant patients. Am J Transplant 2004; 4: 130-1
143. Kaczmarek I, Groetzner J, Adamidis I, et al. Sirolimus impairs gonadal function in heart transplant recipients. Am J Transplant 2004; 4 (7): 1084-8
144. Blume-Jensen P, Jiang G, Hyman R, et al. Kit/stem cell factor receptor-induced activation of phosphatidylinositol 3′-kinase is essential for male fertility. Nat Genet 2000; 24 (2): 157-62
145. Cure P, Pileggi A, Froud T, et al. Alterations of the female reproductive system in recipients of islets grafts. Transplantation 2004; 78: 1576-81
146. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation, section IV: long-term management of the transplant recipient. IV. 10. Pregnancy in renal transplant recipients. Nephrol Dial Transplant 2002; 17 Suppl. 4: 50-5
147. Armenti VT, Radomski JS, Moritz MJ, et al. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. Clin Transpl 2002; 121-30
148. Langer RM, Kahan BD. Incidence, therapy, and consequences of lymphocele after sirolimus-cyclosporine-prednisone immunosuppression in renal transplant recipients. Transplantation 2002; 74 (6): 804-8
149. Giessing M, Budde K. Sirolimus and lymphocele formation after kidney transplantation: an immunosuppressive medication as co-factor for a surgical problem? Nephrol Dial Transplant 2003; 18: 448-9
150. Bischof G, Rockenschaub S, Berlakovich G, et al. Management of lymphoceles after kidney transplantation. Transpl Int 1998; 11 (4): 277-80
151. Dutly AE, Gaspert A, Inci I, et al. The influence of the rapamycin-derivate SDZ RAD on the healing of airway anastomoses. Eur J Cardiothorac Surg 2003; 24 (1): 154-8
152. King-Biggs MB, Dunitz JM, Park SJ, et al. Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation. Transplantation 2003; 75 (9): 1437-43
153. Tan A, Levrey H, Dahm C, et al. Lovastatin induces fibroblast apoptosis in vitro and in vivo: a possible therapy for fibroproliferative disorders. Am J Respir Crit Care Med 1999; 159 (1): 220-7
154. Salas-Prato M, Assalian A, Medhi AZ, et al. Inhibition by rapamycin of PDGF- and bFGF-induced human tendon fibroblast proliferation in vitro. J Glaucoma 1996; 5: 54-9
155. Azzola A, Havryk A, Chhajed P, et al. Everolimus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation after lung transplantation. Transplantation 2004; 77 (2): 275-80
156. Humar A, Ramcharan T, Denny R, et al. Are wound complications after a kidney transplant more common with modern immunosuppression? Transplantation 2001; 72 (12): 1920-3
157. Troppmann C, Pierce JL, Gandhi MM, et al. Higher surgical wound complication rates with sirolimus immunosuppression after kidney transplantation: a matched-pair pilot study. Transplantation 2003; 76 (2): 426-9
158. Valente JF, Hricik D, Weigel K, et al. Comparison of sirolimus vs. mycophenolate mofetil on surgical complications and wound healing in adult kidney transplantation. Am J Transplant 2003; 3: 1128-34
159. Flechner SM, Zhou L, Derweesh I, et al. The impact of sirolimus, mycophenolate mofetil, cycosporine, azathioprine, and steroids on wound healing in 513 kidney-transplant recipients. Transplantation 2003; 76 (12): 1729-34
160. Dean PG, Lund WJ, Larson TS, et al. Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus. Transplantation 2004; 77: 1555-61
161. Husain S, Singh N. The impact of novel immunosuppressive agents in infections in organ transplant recipients and the interactions of these agents with antimicrobials. Clin Infect Dis 2002; 35: 53-61
162. Oz HS, Hughes WT. Novel anti-pneumocystis carinii effects of the immunosuppressant mycophenolate mofetil in contrast to provocative effects of tacrolimus, sirolimus and dexamethasone. J Infect Dis 1997; 175: 901-4
163. Gordon SM, LaRosa SP, Kalmadi S, et al. Should prophylaxis for pneumocystis carinii pneumonia in solid organ transplant recipients ever be discontinued? Clin Infect Dis 1999; 28 (2): 240-6
164. Jørgensen PF, Wang JE, Almlöf M, et al. Sirolimus interfères with the innate response to bacterial products in human whole blood by attenuation of IL-10 production. Scand J Immunol 2001; 53: 184-91
165. Gomez-Cambronero J. Rapamycin inhibits GM-CSF-induced neutrophil migration. FEBS Lett 2003; 550: 94-100
166. Gee I, Trull AK, Charman SC, et al. Sirolimus inhibits oxidative burst activity in transplant recipients. Transplantation 2003; 76 (12): 1766-8
167. Eisen HJ, Tuczu EM, Dorrent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349 (9): 847-58
168. Cruz MC, Goldstein AL, Blankenship J, et al. Rapamycin and less immunosuppressive analogs are toxic to Candida Albicans and Cryptococcus neoformans via FKBP12-dependent inhibition of TOR. Antimicrob Agents Chemother 2001; 45: 3162-70
169. Deborska D, Durlik M, Sadowska A, et al. Human herpesvirus-6 in renal transplant recipients: potential risk factors for the development of human herpesvirus-6 seroconversion. Transplant Proc 2003; 35: 2199-201
170. Kuypers DR, Evenepoel P, Maes BD, et al. Role of immunosuppressive drugs in the development of tissue-invasive cytomegalovirus infection in renal tranplant recipients. Transplant Proc 2002; 34 (4): 1164-70
171. Radisic M, Lattes R, Chapman JF, et al. Risk factors for Pneumocystis carinii pneumonia in kidney transplant recipients: a case-control study. Transpl Infect Dis 2003; 5: 84-93
172. Morelon E, Stern M, Kreis H. Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients. Lancet 2000; 343 (3): 225-6
173. Singer SJ, Tiernan R, Sullivan EJ. Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients. Lancet 2000; 343 (24): 1815-6
174. Mahalati K, Murphy DM, West ML. Bronchiolitis obliterans and organizing pneumonia in renal transplant recipients. Transplantation 2000; 69: 1531-2
175. Haydar AA, Denton M, West A, et al. Sirolimus-induced pneumonitis: three cases and a review of the literature. Am J Transplant 2004; 4: 137-9
176. Lennon A, Finan K, Fitzgerald MX, et al. Interstitial pneumonitis associated with sirolimus (rapamycin) therapy after liver transplantation. Transplantation 2001; 72 (6): 1166-7
177. Avitzur Y, Jimenez-Rivera C, Fecteau A, et al. Interstitial granulomatous pneumonitis associated with sirolimus in a child after liver transplantation. J Pediatr Gastroenterol Nutr 2003; 37 (1): 91-4
178. McWilliams TJ, Levvey BJ, Russell PA, et al. Interstitial pneumonitis associated with sirolimus: a dilemma for lung transplantation. J Heart Lung Transplant 2003; 22: 210-3
179. Digon BJ, Rother KI, Hirshberg B, et al. Sirolimus-induced interstitial pneumonitis in an islet transplant recipient [letter]. Diabetes Care 2003; 26 (11): 3191
180. Morelon E, Stern M, Israel-Biet D, et al. Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients. Transplantation 2001; 72 (5): 787-90
181. Pham PTT, Pham PCT, Danovitch GM, et al. Sirolimus-associated pulmonary toxicity. Transplantation 2004; 77 (8): 1215-20
182. Gross DC, Sasaki TM, Buick MK, et al. Acute respiratory failure and pulmonary fibrosis secondary to administration of mycophenolatemofetil. Transplantation 1997; 64 (11): 1607-9
183. Schrestha NK, Mossad SB, Braun W. Pneumonitis associated with the use of mycophenolate mofetil [letter]. Transplantation 2003; 75 (10): 1762
184. Hong JC, Kahan BD. Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management. Transplantation 2000; 69 (10): 2085-90
185. Babinska A, Markell MS, Salifu MO, et al. Enhancement of human platelet aggregation and secretion induced by rapamycin. Nephrol Dial Transplant 1998; 13: 3153-9
186. Quesniaux VF, Wehrli S, Steiner C, et al. The immunosuppressant rapamycin blocks in vitro responses to hematopoietic cytokines and inhibits recovering but not steady-state hematopoiesis in vivo. Blood 1994; 84 (5): 1543-52
187. Kahan BD, Podbielski J, Napoli KL, et al. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation 1998; 66 (8): 1040-6
188. Augustine JJ, Knauss TC, Schulak JA, et al. Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients. Am J Transplant 2004; 4: 2001-6
189. Edwards C, House A, Shahinian V, et al. Sirolimus-based immunosuppression for transplant-associated thrombotic microangiopathy. Nephrol Dial Transplant 2002; 17: 1524-6
190. Yango A, Morrissey P, Monaco A, et al. Successful treatment of tacrolimus-associated thrombotic microangiopathy with sirolimus conversion and plasma exchange. Clin Nephrol 2002; 58 (1): 77-8
191. Franco A, Hernandez L, Capdevilla L, et al. De novo haemolytic-uremic syndrome/thrombotic microangiopathy in renal transplant patients receiving calcineurin inhibitors: role of sirolimus. Transplant Proc 2003; 35: 1764-6
192. Egidi MF, Cowan PA, Naseer A, et al. Conversion to sirolimus in solid organ transplantation: a single-center experience. Transplant Proc 2003; 35 Suppl. 3A: 131S-7S
193. Langer RM, Van Buren CT, Katz SM, et al. De novo hemolytic uremic syndrome after kidney transplantation in patients treated with cyclosporine-sirolimus combination. Transplantation 2002; 73 (5): 756-60
194. Robson M, Côte I, Abbs I, et al. Thrombotic micro-angiopathy with sirolimus-based immunosuppression: potentiation of calcineurin-inhibitor-induced endothelial damage? Am J Transplant 2003; 3: 324-7
195. Saikali JA, Truong LD, Suki WN. Sirolimus may promote thrombotic microangiopathy. Am J Transplant 2003; 3: 229-30
196. Paramesh AS, Grosskreutz C, Florman SS, et al. Thrombotic microangiopathy associated with combined sirolimus and tacrolimus immunosuppression after intestinal transplantation. Transplantation 2004; 77 (1): 129-31
197. Wilasrusmee C, Da Silva M, Singh B, et al. Morphological and biochemical effects of immunosuppressive drugs in a capillary tube assay for endothelial dysfunction. Clin Transplant 2003; 17 Suppl. 9: 6-12
198. Fortin MC, Raymond MA, Madore F, et al. Increased risk of thrombotic microangiopathy in patients receiving a cyclosporin-sirolimus combination. Am J Transplant 2004; 4: 946-52
199. Reynolds JC, Agodoa LY, Yuan CM, et al. Thrombotic microangiopathy after renal transplantation in the United States. Am J Kidney Dis 2003; 42 (5): 1058-68
200. Barone GW, Gurley BJ, Abul-Ezz SR, et al. Sirolimus-induced thrombotic microangiopathy in a renal transplant recipient. Am J Kidney Dis 2003; 42 (1): 202-6
201. Bramow S, Ott P, Nielsen FT, et al. Cholestasis and regulation of genes related to drug metabolism and biliary transport in rat liver following treatment with cyclosporine A and sirolimus (rapamycin). Pharmacol Toxicol 2001; 89: 133-9
202. Deters M, Klabunde T, Kirchner G, et al. Sirolimus/cyclosporine/ tacrolimus interactions on bile flow and biliary excretion of immunosuppressants in a subchronic bile fistula rat model. Br J Pharmacol 2002; 136 (4): 604-12
203. Francavilla A, Carr BI, Starzl TE, et al. Effects of rapamycin on cultured hepatocyte proliferation and gene expression. Hepatology 1992; 15 (5): 871-7
204. Masterson R, Leikis M, Perkovic V, et al. Sirolimus: a single center experience in combination with calcineurin inhibitors. Transplant Proc 2003; 35 Suppl. 3: 99S-104S
205. Kuypers DR, Herelixka A, Vanrenterghem Y. Clinical use of rapamycin in renal allograft recipients identifies its relevant toxicity profile and raises unsolved questions: a single-center experience. Leuven Collaborative Group for Renal Transplantation. Transplant Proc 2003; 35 Suppl. 3A: 138S-42S
206. van Gelder T, ter Meulen CG, Hené R, et al, editor. Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil. Transplantation 2003; 75 (6): 788-91
207. Neff GW, Montalbano M, Slapak-Green G, et al. A retrospective review of sirolimus (rapamune) therapy in orthotopic liver transplant recipients diagnosed with chronic rejection. Liver Transplant 2003; 9 (5): 477-83
208. Reitamo S, Spuls P, Sassolas B, et al. Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomised controlled trial. Br J Dermatol 2001; 145: 438-45
209. Garrigue V, Canet S, Dereure O, et al. Oral ulcerations in a renal transplant recipient: a mycophenolate mofetil-induced complication? Transplantation 2001; 72 (5): 968-9
210. Shapiro JA, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343 (4): 230-8
211. Evenepoel P, Vanrenterghem Y. Death with functioning graft: a preventable cause of graft loss. Ann Transplant 2001; 6 (4): 17-20
212. Koehl GE, Andrassy J, Guba M, et al. Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation 2004; 77 (9): 1319-26
213. Mathew T, Kreis H, Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant 2004; 18: 446-9
214. Campistol JM, Gutierrez-Dalmau A, Torregrose JV. Conversion to sirolimus: a successful treatment for post-transplantation Kaposi's sarcoma. Transplantation 2004; 77 (5): 760-2
215. Joffe I, Katz I, Seghal S, et al. Lack of change of cancellous bone volume with short-term use of the new immunosuppressant rapamycin in rats. Calcif Tissue Int 1993; 53: 45-52
216. Shui C, Riggs BL, Khosla S. The immunosuppressant rapamycin, alone or with transforming growth factor-β, enhances osteoclast differentiation of RAW264.7 monocyte-macrophage cells in the presence of RANK-ligand. Calcif Tissue Int 2002; 71: 437-46
217. Mikuls TR, Julian BA, Bartolucci A, et al. Bone mineral density changes within six months of renal transplantation. Transplantation 2003; 75 (1): 49-54
218. Thiebaud D, Krieg MA, Gillard-Berguer D, et al. Cyclosporine induces high bone turnover and may contribute to bone loss after heart transplantation. Eur J Clin Invest 1996; 26 (7): 549-55
219. Goodman GR, Dissanayake IR, Sodam BR, et al. Immunosuppressant use without bone loss-implications for bone loss after transplantation. J Bone Miner Res 2001; 16 (1): 72-8
220. Goffin E, Vande Berg B, Devogelaer JP, et al. Post-renal transplant syndrome of transient lower limb joint pain: description under a tacrolimus-based immunosuppression. Clin Nephrol 2003; 59 (2): 98-105
221. Grotz WH, Breitenfeldt MK, Braune SW, et al. Calcineurin inhibitor induced pain syndrome (CIPS): a severe disable complication after organ transplantation. Transpl Int 2001; 14 (1): 16-23
222. Bhandari S, Ens J. Premature osteonecrosis and sirolimus treatment in renal transplantation [case report]. BMJ 2001; 323: 665
223. Finsterer J, Kanzler M. Sirolimus myopathy. Transplantation 2003; 76 (12): 1773-4
224. Aboujaoude W, Milgrom ML, Govani MV. Lymphedema associated with sirolimus in renal transplant recipients. Transplantation 2004; 77 (7): 1094-6
225. Kaplan MJ, Ellis CN, Bata-Csorgo Z, et al. Systemic toxicity following administration of sirolimus (formerly rapamycin) for psoriasis. Arch Dermatol 1999; 135: 553-7
226. Cahill BC, Somerville KT, Crompton JA, et al. Early experience with sirolimus in lung transplant recipients with chronic allograft rejection. J Heart Lung Transplant 2003; 22 (2): 169-76
227. Yatscoff RW, Fryer J, Thliveris JA. Comparison of the effect of rapamycin and FK506 on release of prostacyclin and endothelin in vitro. Clin Biochem 1993; 26 (5): 409-14
228. Mohaupt MG, Vogt B, Frey FJ. Sirolimus-associated eyelid edema in kidney transplant recipients. Transplantation 2001; 72(1): 162-4
229. Wadei H, Gruber SA, El-Amm JM, et al. Sirolimus-induced angioedema. Am J Transplant 2004; 4: 1002-5
230. Hardinger KL, Cornelius LA, Trulock III EP, et al. Sirolimus-induced leukocytoclastic vasculitis. Transplantation 2002; 74 (5): 739-43
231. Pasqualotto AC, Bianco PD, Sukiennik CT, et al. Sirolimus-induced leukocytoclastic vasculitis: the second case reported. Am J Transplant 2004; 4 (9): 1549-51